Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Cancer · 2024

Voranigo (vorasidenib)

The FDA approved Voranigo (vorasidenib) on August 6, 2024 to treat Grade 2 astrocytoma or oligodendroglioma.
Brand name
Voranigo
Generic name
vorasidenib
FDA approval date
August 6, 2024
Approved use (FDA wording)
To treat Grade 2 astrocytoma or oligodendroglioma
Category on this site
Cancer

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.